The embodiments relate to a method and to an arrangement for detecting and, more particularly, counting cells in a cell suspension.
The detection of cells and cell interactions within the same blood sample using magnetoresistive methods is an unresolved problem to date. Such interactions, however, are important for medical diagnostics for inferring a particular clinical picture as quickly as possible.
One of these clinical pictures is thrombocytopenia, e.g., the excessively low number of thrombocytes or platelets in blood. Thrombocytopenia may be the result of a blood coagulation disorder or an increased activity of the immune system against the endogenous thrombocytes (e.g., immunothrombocytopenia). A case of immunothrombocytopenia may occur as an autoimmune disease (e.g., immune thrombocytic purpura or idiopathic thrombocytopenic purpura, ITP), in which the inherent immune system detects and removes thrombocytes. Immunothrombocytopenia may also occur when the number of thrombocytes drastically sinks during an infectious disease. In this case, thrombocytes perform tasks within the immune defense process. In this process, the thrombocytes either directly interact with immune cells (e.g., monocytes), forming immune cell/thrombocyte aggregates, or directly interact with the infiltrated microorganisms (e.g., bacteria, viruses, yeasts/fungi). In both cases, the thrombocytes are detected and removed by monocytes. Monocytes are cells of the immune system that circulate in blood, and the precursors of the macrophages localized in, inter alia, the tissues and of a portion of the dendritic cells. Thrombocytes within such aggregates are no longer available for tasks during blood coagulation or hemostasis. The resulting lowering of the thrombocyte count owing to acute immune reactions may be confused with a coagulation disorder. The rapid differentiation of these two clinical pictures (e.g., coagulation disorder or autoimmune disease) may speed up the diagnosis. The present embodiments allow, inter alia, the counting of immune cell/thrombocyte aggregates in whole blood.
To date, the detection of aggregates of immune cells with thrombocytes is, as far as is known, only realized by optical flow cytometry. This technology requires the specific labeling of both cell types (e.g., immune cells and thrombocytes) using antibodies labeled for fluorescence. Furthermore, the optical flow cytometry requires a complex cleanup of the cell types to be investigated or a removal of interfering cell types such as, for example, red blood cells. Without this cleanup, the detection of the fluorescent dyes used would not be possible.
The scope of the present invention is defined solely by the appended claims and is not affected to any degree by the statements within this summary. The present embodiments may obviate one or more of the drawbacks or limitations in the related art.
It is an object of the present embodiments to specify an improved method and a corresponding arrangement for detecting and, more particularly, quantifying cells in a cell suspension, avoiding the disadvantage stated at the beginning.
The arrangement for quantifying cells, while distinguishing between at least two different sizes of cell types and/or cell conglomerate types in a cell suspension, includes a magnetic field-sensitive sensor having at least one first and second pair of sensor elements, wherein (1) the sensor elements of the first pair have a first spacing of between half and double a first mean size of a first type of cell or cell conglomerate to be measured, (2) the sensor elements of the second pair have a second spacing of between half and double a second mean size of a second type of cell or cell conglomerate to be measured, and (3) a third spacing of the sensor elements of the pairs that are closest to one another is greater than the larger of the two mean sizes. The arrangement also includes a channel for guiding the cell suspension past the sensor elements.
It was identified that a specific sensor geometry makes it possible to distinguish between various types of cells and/or conglomerates in a cell suspension. Advantageously, no cleanup or filtering or dilution is required here; instead, the cell suspension may be left in its initial state. Merely a labeling of at least some of the cells with superparamagnetic particles is required in order to generate a signal at the magnetoresistive sensor.
It is useful if the arrangement includes an evaluation unit for evaluating a first signal of the first pair and a second signal of the second pair, the evaluation unit being designed to evaluate both the time lag between the first and the second signal and the amplitude of the two signals.
The first exemplary embodiment, which will be more particularly elucidated with the aid of
Because the thrombocytes 22 are labeled with superparamagnetic nanoparticles, the individual cells and aggregates are detectable by GMR sensor technology. If an individual thrombocyte 22, a monocyte/thrombocyte aggregate or a thrombocyte aggregate 41, 51 is conducted across the sensor, then characteristic signals are produced. If thrombocytes 22 react with monocytes 21 via specific antigen-antibody interactions, cell/cell aggregates having a mean size of about 25 μm are formed.
The sensor geometry of the sensor depicted in
Other types of cells and cell aggregates that may occur in this example may be clearly distinguished therefrom and from one another on the basis of their characteristic signals.
Therefore, the various cells and aggregates that occur may be distinguished on the basis of the following table. Here, it may be seen that, despite the labeling of only one cell type, different sizes and cell/cell aggregates may be measured by analysis of the different signal forms.
wherein:
Advantageously, what is thus done here is, firstly, the adaptation of the sensor geometry to the expected geometry or size of the analyte to be measured and, secondly, the setting of the spacing between two sensor strips, in order to distinguish immune cell/thrombocyte aggregates (diameter: 15-25 μm) from individual thrombocytes (2-5 μm) in the same sample. The spacing between the pairs 12,13 makes it possible to additionally rule out cell aggregates that are greater than the target structure, e.g., greater than about 25 μm in the present example. Furthermore, the resulting signal combinations make it possible to identify the cell or cell combination just measured.
The following acts are thus advantageously carried out or the advantages include (a) adaptation of the sensor geometry to the size of the analyte (e.g., magnetic particles such as metallic particles or magnetically labeled biochemical particles such as proteins or liposomes and also magnetically labeled biological particles such as animal cells, microorganisms and viruses). A time-of-flight measurement provides information about the size of the analyte. The advantages also include
(b) The arrangement of two sensors having different geometries allows the differentiation of particles of differing size and their composition by an exclusion method. In the method, the form of the individual signal and the temporal sequence of two signals is a specific criterion.
(c) The amplitude of the signal allows the differentiation of particle agglomerates of differing composition according to their magnetization. In this case, one component of the agglomerate is magnetically labeled (thrombocyte 22), whereas the other component remains unlabeled (monocyte 21). The unlabeled component influences the magnetization and size of the entire agglomerate.
(d) The measurement of an analyte may be carried out in complex liquids (including blood, urine, or secretions) without cleanup or dilution acts. An optical transparency is not required.
In the present first example, the cells used (e.g., primary phagocytes of the immune system) are between 15 and 30 μm in size. By contrast, the platelets are between 2 and 5 μm in size. This gives rise to a range for the spacings. For example, it is possible to use between 1 and 4 μm as the spacing between the sensor elements 11 of the first pair 12, and additionally between 20 and 30 μm as the spacing between the sensor elements 11 of the second pair 13 and between 30 and 40 μm as the spacing between the closest sensor elements 11 of both pairs 12, 13. The optimal geometry may be concretized experimentally.
The thrombocytes 22 gain increasing importance during the process of primary immune defense, where they interact in a supporting manner with immune cells or, in the event of ITP, also directly with foreign organisms such as bacteria, viruses or fungi and yeasts. A differentiation between these two causes of a case of thrombocytopenia (e.g., ITP or infection) may be crucial for a subsequent selection of a medicinal treatment.
In the event of a viral disease, thrombocytes 22 are also capable of ingesting and neutralizing them via phagocytosis. During this process, thrombocytes 22 are also capable of presenting MHC-I antigens (found especially on immune cells, but also on thrombocytes 22) on their surface to alert the immune system. A labeling of MHC-1 in blood and the counting of the cells may hint at a case of immunothrombocytopenia. In this case, large cells may be identified as immune cells and small cells as thrombocytes 22.
Endogenous phagocytes are capable of defanging circulating tumor cells identified as foreign bodies by the immune system, by phagocytosis (e.g., swallowing) and subsequent digestion. During this process, the diameter of a phagocyte becomes significantly greater on the one hand, and on the other hand, these cells also present specific antigens (e.g., MHC-1) on their surface during and after completion of the process. The magnetic labeling of these antigens, the determination of cell size and the subsequent counting of these cells provides indirect information about whether the number of circulating tumor cells is normal or increased.
During hemostasis, the viscosity of blood increases owing to the formation of fibrin from fibrinogen. If blood is conducted through a microfluidic channel, the particles move free of friction with the fluid stream within the channel.
If fibrin is formed (the last step during blood coagulation), the viscosity of blood increases continuously until stoppage eventually occurs. If the viscosity increases and the flow velocity of the blood is slowed down, the velocity of particles within the blood also becomes increasingly lower. The slowing down of particles in coagulating blood may be used as a measure of its increasing viscosity and directly correlated with the increasing proportion of insoluble fibrin. Consequently, a time-of-flight measurement may also make it possible to measure the change in viscosity of the blood within the channel.
In this case, the time-of-flight measurement uses, for example, the spacing between the two pairs 12, 13 and the signals generated by the pairs when an analyte passes by.
Since the flow velocity of blood from different donors may vary owing to different initial viscosities, an internal standard allowing determination of the flow velocity at the start of each measurement may be introduced into the sample. Such a standard may include magnetic particles, which may differ from the analyte (very much smaller or very much larger) so that a mix-up with the analyte, (e.g., the actual cells or cell conglomerates), may be ruled out.
For exemplary embodiments 4 and 5, the initial pump output is the same.
In the exemplary embodiments, the starting point was a parallel arrangement of the sensor elements 11 in a Wheatstone bridge. In the arrangement, the individual sensor elements 11 of one pair 12, 13 provide temporally inverted signals, which, in the case of an overlap, leads to the signal sequences explained at the beginning depending on the analytes.
When using sensor elements 11 not interconnected to form a Wheatstone bridge or when using a diagonal arrangement of the sensor elements 11 in the Wheatstone bridge according to
It is to be understood that the elements and features recited in the appended claims may be combined in different ways to produce new claims that likewise fall within the scope of the present invention. Thus, whereas the dependent claims appended below depend from only a single independent or dependent claim, it is to be understood that these dependent claims may, alternatively, be made to depend in the alternative from any preceding or following claim, whether independent or dependent, and that such new combinations are to be understood as forming a part of the present specification.
While the present invention has been described above by reference to various embodiments, it may be understood that many changes and modifications may be made to the described embodiments. It is therefore intended that the foregoing description be regarded as illustrative rather than limiting, and that it be understood that all equivalents and/or combinations of embodiments are intended to be included in this description.
Number | Date | Country | Kind |
---|---|---|---|
102012210598.0 | Jun 2012 | DE | national |
The present patent document is a §371 nationalization of PCT Application Serial Number PCT/EP2013/061348, filed Jun. 3, 2013, designating the United States, which is hereby incorporated by reference, and this patent document also claims the benefit of DE 10 2012 210 598.0, filed on Jun. 22, 2012, which is also hereby incorporated by reference.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/EP13/61348 | 6/3/2013 | WO | 00 |